Although impressive advances have been made in determining the genetic and molecular causes of disease, treatment for many complex diseases remains inadequate. Despite compelling unmet medical needs and new insights into disease pathobiology, new drug approvals for complex diseases have stagnated. A new paradigm for drug development is needed, and key concepts from network medicine and systems pharmacology may be essential to this effort. Clinical Pharmacology & Therapeutics (2013); 93 1, 26–28. doi:10.1038/clpt.2012.207
No takes yet. Share an insight, caveat, or question.
Silverman et al. (2012) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: